These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anthrax vaccines: a development update. Little SF BioDrugs; 2005; 19(4):233-45. PubMed ID: 16128606 [TBL] [Abstract][Full Text] [Related]
3. Advances in the development of next-generation anthrax vaccines. Friedlander AM; Little SF Vaccine; 2009 Nov; 27 Suppl 4():D28-32. PubMed ID: 19837282 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a subunit vaccine against Bacillus anthracis. Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Park YS; Lee JH; Hung CF; Wu TC; Kim TW Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494 [TBL] [Abstract][Full Text] [Related]
7. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes. Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664 [TBL] [Abstract][Full Text] [Related]
8. Potentiation of anthrax vaccines using protective antigen-expressing viral replicon vectors. Wang HC; An HJ; Yu YZ; Xu Q Immunol Lett; 2015 Feb; 163(2):206-13. PubMed ID: 25102364 [TBL] [Abstract][Full Text] [Related]